NADAC acquisition cost data for MOTEGRITY 1 MG TABLET. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 54092054601 | $15.64 | 2022-01-03 | Rx |
| 54092054601 | $15.64 | 2022-01-03 | Rx |
| 54092054601 | $15.64 | 2022-01-03 | Rx |
| 54092054601 | $15.64 | 2022-01-03 | Rx |
| 54092054601 | $15.64 | 2022-01-03 | Rx |
| 54092054601 | $15.64 | 2022-01-03 | Rx |
| 54092054601 | $15.64 | 2022-01-03 | Rx |
| 54092054601 | $15.64 | 2022-01-03 | Rx |
| 54092054601 | $15.64 | 2022-01-03 | Rx |
| 54092054601 | $15.64 | 2022-01-03 | Rx |
Generic: Prucalopride Succinate | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $6.0M | 11,537 | 4,728 | $14.27 |
| 2020 | $22.6M | 39,360 | 10,280 | $14.75 |
| 2021 | $33.4M | 51,759 | 12,958 | $15.85 |
| 2022 | $48.7M | 70,305 | 17,188 | $16.88 |
| 2023 | $61.9M | 82,065 | 19,413 | $17.69 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $7.9M | 9,974 | 2,464 |
| New York | $4.8M | 6,647 | 1,559 |
| North Carolina | $3.2M | 4,273 | 1,020 |
| Pennsylvania | $3.1M | 4,441 | 997 |
| Florida | $3.1M | 3,793 | 1,026 |
| Texas | $2.8M | 3,661 | 1,000 |
| Connecticut | $2.8M | 3,416 | 809 |
| Massachusetts | $2.5M | 3,371 | 718 |
| Ohio | $2.2M | 3,178 | 748 |
| Indiana | $2.1M | 2,697 | 619 |
| New Jersey | $2.0M | 2,403 | 629 |
| Georgia | $1.8M | 2,315 | 588 |
| Michigan | $1.7M | 2,102 | 552 |
| South Carolina | $1.5M | 2,038 | 493 |
| Missouri | $1.5M | 2,042 | 475 |
| Kentucky | $1.4M | 1,962 | 419 |
| Illinois | $1.4M | 1,904 | 470 |
| Virginia | $1.4M | 1,811 | 468 |
| Tennessee | $1.4M | 1,888 | 445 |
| Wisconsin | $1.1M | 1,490 | 373 |
| Colorado | $1.1M | 1,392 | 333 |
| Maryland | $918.8K | 1,049 | 297 |
| Alabama | $884.8K | 1,291 | 328 |
| Arizona | $840.8K | 1,095 | 287 |
| Louisiana | $825.9K | 1,310 | 285 |
| Minnesota | $743.7K | 1,002 | 234 |
| Washington | $640.7K | 916 | 206 |
| Nebraska | $579.9K | 871 | 178 |
| Iowa | $550.7K | 854 | 180 |
| Oregon | $455.8K | 643 | 182 |
| Maine | $453.5K | 541 | 125 |
| Oklahoma | $397.9K | 549 | 124 |
| Utah | $385.5K | 544 | 144 |
| Kansas | $351.3K | 458 | 112 |
| Rhode Island | $349.6K | 566 | 107 |
| New Hampshire | $344.7K | 417 | 88 |
| Mississippi | $300.0K | 413 | 98 |
| Idaho | $247.8K | 341 | 85 |
| Arkansas | $239.1K | 298 | 82 |
| West Virginia | $236.0K | 311 | 81 |
| Nevada | $217.5K | 271 | 84 |
| South Dakota | $189.7K | 293 | 64 |
| Delaware | $184.7K | 238 | 73 |
| Vermont | $163.1K | 194 | 49 |
| Puerto Rico | $119.5K | 214 | 44 |
| Montana | $110.9K | 137 | 38 |
| Hawaii | $106.6K | 130 | 38 |
| New Mexico | $61.8K | 82 | 35 |
| District of Columbia | $56.4K | 84 | 29 |
| Alaska | $40.7K | 46 | 14 |
| Wyoming | $29.9K | 39 | 12 |
| North Dakota | $17.9K | 23 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.